A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples

AAPS Journal

Volumn 9, Issue 1, 2007, Pages

  Bauer, Robert J ^a   Guzy, Serge ^a   Ng, Chee ^b  

^a XOMA Corporation   (United States)

^b CTRC Institute for Drug Development   (United States)

Author keywords

Clinical; Computation methods; Pharmacodynamics; Pharmacokinetics; Population; Software

Indexed keywords

DRUG;

ALGORITHM; BAYES THEOREM; COMPUTER ANALYSIS; COMPUTER INTERFACE; COMPUTER SIMULATION; DATA ANALYSIS SOFTWARE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG RESEARCH; KERNEL METHOD; MEASUREMENT ERROR; MONTE CARLO METHOD; POPULATION MODEL; RANDOM SAMPLE; REVIEW; SAMPLING ERROR; STATISTICAL ANALYSIS; STATISTICAL DISTRIBUTION; THEORETICAL MODEL; BIOLOGICAL MODEL; COMPUTER PROGRAM; HEALTH SURVEY; HUMAN; METHODOLOGY; PHARMACOKINETICS; PHARMACOLOGY; STATISTICAL MODEL; STATISTICS;

ALGORITHMS; COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PHARMACOKINETICS; PHARMACOLOGY; POPULATION SURVEILLANCE; SOFTWARE;

EID: 34247887681     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj0901007     Document Type: Review

References (47)

1. Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn. 2006;33:227-279.
2. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetics parameters. 1. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1980;8:553-571.
3. Pillai G, Mentre F, Steimer JL. Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science. J Pharmacokinet Pharmacodyn. 2005;32:161-183.
4. Mandema JW. Population pharmacokinetics and pharmacodynamics. In: Welling PG, Tse FLS, eds. Pharmacokinetics. vol. 67. 2nd ed. New York, NY Marcel Dekker, Inc.; 1995:411-450.
5. Roe DJ. Comparison of population pharmacokinetic modeling methods using simulated data: results from the population modeling workgroup. Stat Med. 1997;16:1241-1262.
6. Aarons L. Software for population pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 1999;36:255-264.
7. Mentre F. Mallet A, Steiner JL. Hyperparameter estimation using stochastic approximation with application to population pharmacokinetics. Biometrics. 1988;44:673-683.
8. Bauer RJ, Guzy S. Monte Carlo parametric expectation maximization (MC-PEM) method for analyzing population pharmacokinetic/pharmacodynamic data. In: D'Argenio DZ, ed. Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis. vol. 3. Boston, MA: Kluwer Academic Publishers; 2004:135-163.
9. Best NG, Tan KK, Spiegelhalter DJ. Estimation of population pharmacokinetics using the Gibbs sampler. J Pharmacokinet Biopharm. 1995;23:407-435.
10. Lunn DJ, Best N, Thomas A, Wakefield J, Spiegelhalter D. Bayesian analysis of population PK/PD models: general concepts and software. J Pharmacokinet Pharmacodyn. 2002;29:271-307.
11. Beal SL, Sheiner LB. NONAIEM Users Guide - Part VII. Hanover, MD: Globomax, Inc; 1992.
12. Users Guides NONMEM. [computer program]. Version V. Hanover, MD: Globomax, Inc; 1989-1998.
13. PDx-MCPEM Users Guide [computer program]. Version 1.0. Hanover, MD: Globomax, Inc; 2006.
14. S-ADAPT/MCPEM User's Guide [computer program]. Version 1.52. Berkeley, CA.; 2006.
15. Monolix Users Manual [computer program]. Version 1. 1. Orsay, France: Laboratoire de Mathematiques, U. Paris-Sud; 2005.
16. PKBUGS software [computer program]. Version 2.0. Cambridge, UK: MRC Biostatistics Unit; 2006.
17. Davidian M, Giltinan DM. Nonlinear Models for Repeated Measurement Data. New York, NY: Chapman and Hall; 1995.
18. Lindstrom ML, Bates DM. Nonlinear mixed effects models for repeated measures data. Biometrics. 1990;46:673-687.
19. Pinheiro JC, Bates DM. Approximations to the Log-likelihood function in the nonlinear mixed-effects model. J Comput Graph Statist. 1995;4:12-35.
20. Beal SL, Sheiner LB. Estimating population kinetics. Crit Rev Biomed Eng. 1982;8:195-222.
21. Ette EI, Kelman AW, Howie CA, Whiting B. Analysis of animal pharmacokinetic data: performance of the one point per animal design. J Phamacokinet Biopharm. 1995;23:551-566.
22. Ette EI, Sun H, Ludden TM. Balanced designs in longitudinal population pharmacokinetic studies. J Clin Pharmacol. 1998;38:417-423.
23. Jones CD, Sun H. Ette EI. Designing cross-sectional population pharmacokinetic studies: implications for pediatric and animal studies. Clin Res Pr Drug Regul Aff. 1996;13:133-165.
24. White DB, Walawander CA, Tung Y, Grasela TH. An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis. J Pharmacokinet Biopharm. 1991;19:87-112.
25. SAS online documentation, SAS/STAT Users Guide, NLMIXED procedure [computer program]. Version 8. Cary, NC: SAS Institute, Inc.; 2005.
26. Jonsson S, Kjellsson MC, Karlsson MO. Estimating bias in population parameters for some models for repeated measures ordinals data using NONMEM and NLMIXED. J Pharmacokinet Pharmacodyn. 2004;31:299-320.
27. Schumitzky A. EM algorithms and two stage methods in pharmacokinetics population analysis. In: D'Argenio DZ, ed. Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis. vol. 2. Boston, MA: Kluwer Academic Publishers; 1995:145-160.
28. Mentre F, Gomeni R. A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmcokinetics. J Biopharm Stat. 1995;5:141-158.
29. Walker S. An EM algorithm for nonlinear random effects models. Biometrics. 1996;52:934-944.
30. Lavielle M. SAEM in MATLAB: an alternative to linearization (software presentation). Presented at: PAGE Meeting; June 17-18, 2004; Uppsala, Sweden. Uppsala, Sweden: Population Approach Group Europe; 2004: Abstract 544.
31. Steimer JL, Mallet A, Golmard JL, Boisvieux JF. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev. 1984;15:265-292.
32. Lindstrom MJ, Bates DM. Newton-Raphson and EM algorithms for linear mixed-effects models for repeated-measures data. J Am Stat Assoc. 1988;83:1014-1022.
33. Aarons L. The estimation of population pharmacokinetic parameters using an EM algorithm. Comput Methods Programs Biomed. 1993;41:9-16.
34. Thermo Kinetica software [computer program]. Version 4.4.1. Waltham, MA: Thermo Electron Corporation; 1997-2007.
35. Gomeni R, Pineau G, Mentre F. Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package. Anticancer Res. 1994;14:2321-2326.
36. Popkinetics software [computer program]. Version 1.0. University of Washington Seattle; 2006.
37. Zhou Z, Rodman JH, Flynn PM, Robbins BL, Wilcox CK, D'Argenio DZ. Model for intracellular lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents. Antimicrob Agents Chemother. 2006;50:2686-2694.
38. Dokoumetzidis A, Aarons L. Propagation of population pharmacokinetic information using a Bayesian approach: comparison with meta-analysis. J Pharmacokinet Pharmacodyn. 2005;32:401-418.
39. Gilks WR. Full conditional distributions. In: Gilks WR, Richardson S, Spiegelhalter DJ, eds. Markov Chain Monte Carlo in Practice. New York, NY: Chapman and Hall; 1996:75-88.
40. Gilks WR, Richardson S, Spiegelhalter DJ. Introducing Markov chain Monte Carlo. In: Gilks WR, Richardson S, Spiegelhalter DJ, eds. Markov Chain Monte Carlo in Practice New York, NY: Chapman and Hall; 1996:1-19.
41. Bennett JE, Racine-Poon A, Wakefield AJ. MCMC for nonlinear heirarchical models. In: Gilks WR, Richardson S, Spiegelhalter DJ, eds. Markov Chain Monte Carlo in Practice. New York, NY: Chapman and Hall; 1996:339-357.
42. Gueroguieva I, Aarons L, Rowland M. Diazepam pharmacokinetics from preclinical to Phase 1 using a Bayesian population physiologically based pharmacokinetics model with informative prior distributions in Winbugs. J Pharmacokinet Pharmacodyn. 2006;33:1-24.
43. ADAPT II Users Guide. Pharmacokinetic/Pharmacodynamic Systems Analysis Software. [computer program]. Version (Release) 4. Los Angeles, CA: Biomedical Simulations Resource, University of Southern California; 1997.
44. Ng CM, Joshi A, Dedrick R, Garovoy M, Bauer R. Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm Res. 2005;22:1088-1100.
45. Mu S, Ludden TM. Estimation of population pharmacokinetic parameters in the presence of non-compliance. J Pharmacokinet Pharmacodyn. 2003;30:53-81.
46. Duffull SB, Kirkpatrick CJ, Green B, Holford NH. Analysis of population pharmcokinetic data using NONMEM and Winbugs. J Biopharm Stat. 2005;15:53-73.
47. Girard P, Mentre F. A comparison of estimation methods in nonlinear mixed effects models using a blind analysis. Presented at: PAGE Meeting; June 16-17, 2005; Pamplona, Spain. Population Approach Group Europe; 2005: Abstract 834.